Electrophysiological Cardiac Liabilities
The Challenge
Traditional patch-clamp assays are typically performed on isolated cells and do not capture the behavior of electrically connected cardiac tissues. This limits their ability to detect drug-induced effects on ion channels in a functional syncytium, potentially leading to missed early safety signals. As a result, the predictive power of preclinical cardiac screening is reduced, increasing the risk of downstream failure.
Our Solution
We provide Extracellular Field Potential Duration (EFPD) measurements as a direct, MEA-like electrophysiological readout from functional cardiac tissues. EFPD sensitively detects subtle changes in electrical activity caused by drug-induced ion channel modulation, such as EFPD prolongation (a surrogate for QT prolongation) and early signs of arrhythmia. When combined with contractility and morphology readouts, it enables a multidimensional and clinically relevant cardiac risk assessment.
